During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...

“That, to me, is surprising and new and exciting.” Analyzing activity of dopamine receptors also reinforced the role this neurotransmitter plays in changing stages of sexual behavior. Miyasaka ...